James Duckenfield, CEO of Glass Pharms®, explains why we may be underestimating the pharmaceutical potential of cannabis, and how research, formulation and more controlled delivery could help realise it.
German medicinal cannabis distributor Fette Pharma GmbH has reported the successful completion of a strategic restructuring, almost seven months after an investor consortium led by entrepreneur Jörg Löser acquired the Egelsbach-based company in September 2025.
In the first of a series of interviews focused on the expert contributors to Prohibition Partners’ newly launched Insights Hub, we sat down with Linnea to discuss the increasing importance of GMP certification and pharmaceutical discipline in a rapidly growing cannabis market.
Welcome to Business of Cannabis’ new weekly strategic digest tracking the financial health, market moves, and corporate developments shaping the European cannabis sector.
In recent years, the pharmaceutical landscape has witnessed a seismic shift as cannabinoids transition from niche alternatives to mainstream medical solutions.
Denmark’s medical cannabis Pilot Programme has seen patient numbers grow by more than 90% between Q2 2022 and Q2 2023.
Pharmaceutical cannabis industry sales are expected to grow by over 20% over the next four years, from $1.14b to $1.37b by 2027.
